Alimera Sciences (NASDAQ:ALIM) Upgraded to “Buy” by StockNews.com

StockNews.com upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a hold rating to a buy rating in a research note issued to investors on Monday morning.

Separately, Maxim Group began coverage on Alimera Sciences in a research report on Monday, March 25th. They issued a buy rating and a $10.00 price objective on the stock.

Alimera Sciences Stock Performance

Shares of ALIM opened at $3.31 on Monday. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.39 and a quick ratio of 2.31. Alimera Sciences has a one year low of $1.56 and a one year high of $4.38. The firm has a market capitalization of $173.28 million, a P/E ratio of -1.53 and a beta of 1.18. The business has a fifty day moving average of $3.72 and a 200 day moving average of $3.63.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The company had revenue of $26.31 million for the quarter, compared to the consensus estimate of $25.10 million. During the same period in the prior year, the firm posted ($0.54) EPS. As a group, sell-side analysts anticipate that Alimera Sciences will post 0.03 EPS for the current year.

Hedge Funds Weigh In On Alimera Sciences

Several large investors have recently made changes to their positions in ALIM. Worth Venture Partners LLC purchased a new position in shares of Alimera Sciences in the third quarter valued at about $1,840,000. AIGH Capital Management LLC purchased a new position in shares of Alimera Sciences in the third quarter valued at about $7,355,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Alimera Sciences in the third quarter worth about $12,349,000. 99.83% of the stock is currently owned by hedge funds and other institutional investors.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).